A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Prior treatment

• Participants with history or evidence of chronic pancreatic disease; pancreatic injury or acute pancreatitis within 6 months before screening.
• Participants with a recent history or planned surgical procedures or medications intended to produce significant weight loss.

Other illness

• Participants with other chronic liver diseases.
• Participants with evidence or history of decompensated liver disease or hepatocellular carcinoma.
• Participants with history of Type 1 diabetes mellitus or major Type 2 diabetes complications.
• Participants with current or history of excessive alcohol intake.

Lab values

• Participants with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>=5 times upper limit normal (ULN).

• Participants aged between 18 and 75 years at enrollment.
• Participants with compensated cirrhosis due to MASH, confirmed by non-invasive assessments.
• Participants with history or presence of at least two components of metabolic syndrome.